J Korean Med Sci.  2020 Jul;35(29):e213. 10.3346/jkms.2020.35.e213.

Neutrophil-mediated Thrombosis and NETosis in Behçet's Disease: a Hypothesis

• Batu ED

• KMID: 2504697
• DOI: http://doi.org/10.3346/jkms.2020.35.e213

Figure

• 

  Fig. 1 Schematic representation of thromboinflammation in Behçet's disease. Activated neutrophils produce ROS, which induces NETosis. NETs cause endothelial damage, activate platelets, and induce thrombin generation. Activated platelet degranulate and release pro-inflammatory cytokines that stimulate neutrophils further. Platelet aggregation also damages endothelium and induces thrombin generation, which finally leads to the formation of the fibrin clot. Besides, ROS produced by neutrophils modifies fibrinogen, which makes the fibrin clot more resistant to plasmin-induced lysis.ROS = reactive oxygen species, NETs = neutrophil extracellular traps.

Reference

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013; 65(1):1–11. PMID: 23045170.

2. Batu ED. Diagnostic/classification criteria in pediatric Behçet's disease. Rheumatol Int. 2019; 39(1):37–46. PMID: 30430200.

3. Rodríguez-Carballeira M, Solans R, Larrañaga JR, García-Hernández FJ, Rios-Fernández R, Nieto J, et al. Venous thrombosis and relapses in patients with Behçet's disease. Descriptive analysis from Spanish network of Behçet's disease (REGEB cohort). Clin Exp Rheumatol. 2018; 36(6):Suppl 115. 40–44.

4. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. Nat Rev Rheumatol. 2018; 14(2):119.

5. Kushner A, West DW, Pillarisetty LS. Virchow Triad. Treasure Island, FL: StatPearls;2020.

6. La Regina M, Gasparyan AY, Orlandini F, Prisco D. Behcet's disease as a model of venous thrombosis. Open Cardiovasc Med J. 2010; 4(1):71–77. PMID: 20360979.

7. Becatti M, Emmi G, Silvestri E, Bruschi G, Ciucciarelli L, Squatrito D, et al. Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Behçet disease. Circulation. 2016; 133(3):302–311. PMID: 26585672.

8. Emmi G, Becatti M, Bettiol A, Hatemi G, Prisco D, Fiorillo C. Behçet's syndrome as a model of thrombo-inflammation: the role of neutrophils. Front Immunol. 2019; 10:1085. PMID: 31139195.

9. Alibaz-Oner F, Ergelen R, Mutis A, Erturk Z, Asadov R, Mumcu G, et al. Venous vessel wall thickness in lower extremity is increased in male patients with Behcet's disease. Clin Rheumatol. 2019; 38(5):1447–1451. PMID: 30758790.

10. Le Joncour A, Martos R, Loyau S, Lelay N, Dossier A, Cazes A, et al. Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease. Ann Rheum Dis. 2019; 78(9):1274–1282. PMID: 31147357.

11. Seyahi E, Gjoni M, Durmaz EŞ, Akbaş S, Sut N, Dikici AS, et al. Increased vein wall thickness in Behçet disease. J Vasc Surg Venous Lymphat Disord. 2019; 7(5):677–684.e2. PMID: 30777674.

12. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004; 303(5663):1532–1535. PMID: 15001782.

13. Sørensen OE, Borregaard N. Neutrophil extracellular traps - the dark side of neutrophils. J Clin Invest. 2016; 126(5):1612–1620. PMID: 27135878.

14. Elkon KB. Review: Cell death, nucleic acids, and immunity: inflammation beyond the grave. Arthritis Rheumatol. 2018; 70(6):805–816. PMID: 29439290.

15. Safi R, Kallas R, Bardawil T, Mehanna CJ, Abbas O, Hamam R, et al. Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Behçet's disease. J Dermatol Sci. 2018; 92(2):143–150. PMID: 30237006.

16. Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell Biol. 2009; 184(2):205–213. PMID: 19153223.

17. Ducroux C, Di Meglio L, Loyau S, Delbosc S, Boisseau W, Deschildre C, et al. Thrombus neutrophil extracellular traps content impair tPA-induced thrombolysis in acute ischemic stroke. Stroke. 2018; 49(3):754–757. PMID: 29438080.

18. Laridan E, Denorme F, Desender L, François O, Andersson T, Deckmyn H, et al. Neutrophil extracellular traps in ischemic stroke thrombi. Ann Neurol. 2017; 82(2):223–232. PMID: 28696508.

19. Mangold A, Alias S, Scherz T, Hofbauer T, Jakowitsch J, Panzenböck A, et al. Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size. Circ Res. 2015; 116(7):1182–1192. PMID: 25547404.

20. Mejía JC, Espinosa G, Tàssies D, Reverter JC, Cervera R. Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy. Clin Exp Rheumatol. 2014; 32(4):Suppl 84. S67–71. PMID: 25068444.

21. Guo L, Rondina MT. The era of thromboinflammation: Platelets are dynamic sensors and effector cells during infectious diseases. Front Immunol. 2019; 10:2204. PMID: 31572400.

22. Maugeri N, Campana L, Gavina M, Covino C, De Metrio M, Panciroli C, et al. Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J Thromb Haemost. 2014; 12(12):2074–2088. PMID: 25163512.

23. Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD. Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol. 2015; 11(11):1781–1794. PMID: 26239119.

24. Batu ED, Arici ZS, Bilginer Y, Özen S. Current therapeutic options for managing familial Mediterranean fever. Expert Opin Orphan Drugs. 2015; 3(9):1063–1073.

25. Angelidis C, Kotsialou Z, Kossyvakis C, Vrettou AR, Zacharoulis A, Kolokathis F, et al. Colchicine pharmacokinetics and mechanism of action. Curr Pharm Des. 2018; 24(6):659–663. PMID: 29359661.

26. Reddel CJ, Pennings GJ, Curnow JL, Chen VM, Kritharides L. Procoagulant effects of low-level platelet activation and its inhibition by colchicine. Thromb Haemost. 2018; 118(4):723–733. PMID: 29554700.

27. Shah B, Allen N, Harchandani B, Pillinger M, Katz S, Sedlis SP, et al. Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: a pilot study in healthy subjects. Inflammation. 2016; 39(1):182–189. PMID: 26318864.

28. Krumb E, Lefebvre C, Peeters A, Hermans C. Cerebral venous thrombosis revealing Behçet's disease in a Moroccan patient: a case report and literature review. SAGE Open Med Case Rep. 2018; 6:2050313X18767053.

29. Nonaka D, Takase H, Machii M, Ohno K. Colchicine therapy for deep vein thrombosis in a patient with vascular-type Behçet disease: a case report. Medicine (Baltimore). 2020; 99(16):e19814. PMID: 32312000.

30. Yilmaz S, Cimen KA. Pulmonary artery aneurysms in Behçet's disease. Rheumatol Int. 2010; 30(10):1401–1403. PMID: 19693504.

31. Garcia RJ, Francis L, Dawood M, Lai ZW, Faraone SV, Perl A. Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 2013; 65(5):1313–1318. PMID: 23400548.

32. Lai ZW, Hanczko R, Bonilla E, Caza TN, Clair B, Bartos A, et al. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012; 64(9):2937–2946. PMID: 22549432.

33. Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, et al. N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol. 2011; 186(7):4396–4404. PMID: 21346230.

34. Yavuz S, Akdeniz T, Hancer V, Bicakcigil M, Can M, Yanikkaya-Demirel G. Dual effects of testosterone in Behcet's disease: implications for a role in disease pathogenesis. Genes Immun. 2016; 17(6):335–341. PMID: 27467286.